Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alder BioPharmaceuticals Inc.

www.alderbio.com

Latest From Alder BioPharmaceuticals Inc.

Amgen’s Playing To Its R&D Strengths, Which No Longer Include Neuroscience

The company will focus on core therapeutics areas like oncology and cardiovascular disease, but left open the possibility of future work in neuroscience with a genetic basis for drug development.

Research and Development Strategies Neurology

Acorda Restructures, Cuts Jobs By 25% With No Deals, Big Debt On The Horizon

Acorda is cutting jobs to save $21m annually and otherwise lowering expenses for a total of $60m in reduced costs in 2020 to focus on marketing Inbrija, but looming overhead is $345m in debt due in 2021. Meanwhile, ex-US partners and company buyers appear nowhere in sight.

Business Strategies Companies

UCB To Buy Ra for $2.1bn And Plays Down Antitrust Fears

The deal, welcomed by analysts, means that the Belgian drug maker has two late-stage products for the rare disease myasthenia gravis to challenge Alexion's Soliris.
M & A Companies

Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It

Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alder BioPharmaceuticals Inc.
  • Senior Management
  • Robert W Azelby, CEO
    Carlos Campoy, CFO
    John A Latham, PhD, CSO
    Nadia Dac, Chief Commercial Officer
    Erin Lavelle, COO
  • Contact Info
  • Alder BioPharmaceuticals Inc.
    Phone: (425) 205-2900
    11804 North Creek Pkwy. S.
    Bothell, WA 98011
    USA
UsernamePublicRestriction

Register